MCID: ADN012
MIFTS: 43

Adenocarcinoma in Situ

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Adenocarcinoma in Situ

MalaCards integrated aliases for Adenocarcinoma in Situ:

Name: Adenocarcinoma in Situ 12 44 15 72

Classifications:



External Ids:

Disease Ontology 12 DOID:4943
MeSH 44 D065311
NCIt 50 C4123
SNOMED-CT 68 51642000
UMLS 72 C0334276

Summaries for Adenocarcinoma in Situ

Disease Ontology : 12 An in situ carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Adenocarcinoma in Situ is related to suppressor of tumorigenicity 3 and appendix adenocarcinoma. An important gene associated with Adenocarcinoma in Situ is CDKN2A (Cyclin Dependent Kinase Inhibitor 2A), and among its related pathways/superpathways are Endometrial cancer and Pathways in cancer. The drugs Vaccines and Immunologic Factors have been mentioned in the context of this disorder. Affiliated tissues include lung, cervix and testes, and related phenotypes are Reduced mammosphere formation and cellular

Related Diseases for Adenocarcinoma in Situ

Diseases in the Adenocarcinoma family:

Adenocarcinoma in Situ

Diseases related to Adenocarcinoma in Situ via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 224)
# Related Disease Score Top Affiliating Genes
1 suppressor of tumorigenicity 3 30.5 CDKN2A CDKN1A
2 appendix adenocarcinoma 30.5 KRT7 KRT20 CDX2
3 endometrial adenocarcinoma 30.4 KRT7 KRAS CDKN2A
4 cervical adenocarcinoma 30.3 KRT7 KRT20 CDX2 CDKN2A CDKN1A
5 bronchiolo-alveolar adenocarcinoma 30.3 KRT7 KRT20 KRAS CDX2
6 endometrial mucinous adenocarcinoma 30.3 PAX2 CDKN2A
7 peritoneum cancer 30.3 PAX8 KRT7
8 duodenum adenocarcinoma 30.2 KRT7 KRAS CDX2
9 dermoid cyst 30.2 KRT7 KRT20
10 villous adenoma 30.0 KRT20 KRAS CDX2
11 glandular cystitis 30.0 KRT7 KRT20 CDX2
12 ovarian mucinous neoplasm 30.0 KRT7 KRT20 CDX2
13 cystic teratoma 30.0 KRT7 KRT20 CDX2
14 transitional cell carcinoma 30.0 KRT7 KRT20 CDKN2A
15 papillary carcinoma 29.9 PAX8 KRT7 KRT20
16 colorectal adenocarcinoma 29.9 KRT7 KRT20 KRAS CDX2
17 mucinous adenocarcinoma 29.8 KRT7 KRT20 KRAS CDX2 CDKN2A
18 mammary paget's disease 29.8 KRT7 KRT20
19 endocervical adenocarcinoma 29.7 PAX8 PAX2 KRT7 KRT20 CDX2 CDKN2A
20 pseudomyxoma peritonei 29.7 KRT7 KRT20 KRAS CDX2
21 intrahepatic cholangiocarcinoma 29.6 KRT7 KRT20 KRAS CDX2
22 colon adenocarcinoma 29.6 KRT20 KRAS CDKN1A
23 papilloma 29.4 KRT7 KRT20 CDKN2A CDKN1A
24 large cell neuroendocrine carcinoma 29.3 KRT7 KRT20
25 barrett esophagus 29.3 MCM2 KRT7 KRT20 CDX2 CDKN2A
26 lung cancer susceptibility 3 28.4 KRT7 KRT20 KRAS H19 CDX2 CDKN2A
27 endometrial cancer 28.4 PAX8 KRT7 KRAS H19 CDKN2A CDKN1A
28 cholangiocarcinoma 28.1 KRT7 KRT20 KRAS H19 CDX2 CDKN2A
29 lung cancer 27.8 KRT7 KRT20 KRAS H19 CDKN2A CDKN1A
30 in situ pulmonary adenocarcinoma 11.4
31 early invasive cervical adenocarcinoma 11.2
32 adenocarcinoma 10.9
33 inverted transitional papilloma 10.6 KRT7 CDKN2A
34 ovary neuroendocrine neoplasm 10.6 KRT7 CDX2
35 anus adenocarcinoma 10.6 KRT7 CDX2
36 mucinous adenofibroma 10.6 KRT7 CDX2
37 bladder carcinoma in situ 10.6 KRT7 CDKN2A
38 adenoid basal cell carcinoma 10.6 KRT7 CDKN2A
39 vulvar disease 10.6 KRT7 CDKN2A
40 cystic basal cell carcinoma 10.6 KRT7 KRT20
41 epithelial predominant wilms' tumor 10.6 KRT7 CDX2
42 anal canal carcinoma 10.6 KRT7 CDKN2A
43 renal pelvis adenocarcinoma 10.6 PAX8 KRT7
44 malignant syringoma 10.6 KRT7 KRT20
45 transverse colon cancer 10.6 KRT7 KRT20
46 alveoli adenoma 10.6 KRT7 KRAS
47 seminal vesicle adenocarcinoma 10.6 KRT7 KRT20
48 endosalpingiosis 10.6 PAX8 KRT7
49 sensory organ benign neoplasm 10.5 PAX8 KRT7
50 well-differentiated liposarcoma 10.5 KRT7 CDKN2A

Graphical network of the top 20 diseases related to Adenocarcinoma in Situ:



Diseases related to Adenocarcinoma in Situ

Symptoms & Phenotypes for Adenocarcinoma in Situ

GenomeRNAi Phenotypes related to Adenocarcinoma in Situ according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.1 CLDN1 H19 KRAS KRT7 MCM2 PAX8

MGI Mouse Phenotypes related to Adenocarcinoma in Situ:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.97 CDKN1A CDKN2A CDX2 KRAS KRT7 MCM2
2 embryo MP:0005380 9.87 CDKN1A CDKN2A CDX2 KRAS MCM2 PAX2
3 endocrine/exocrine gland MP:0005379 9.8 CDKN1A CDKN2A CDX2 KRAS MCM2 PAX2
4 neoplasm MP:0002006 9.55 CDKN1A CDKN2A CDX2 KRAS MCM2
5 pigmentation MP:0001186 9.26 CDKN2A KRAS MCM2 PAX2
6 renal/urinary system MP:0005367 9.1 CDKN1A CLDN10 KRAS KRT7 PAX2 PAX8

Drugs & Therapeutics for Adenocarcinoma in Situ

Drugs for Adenocarcinoma in Situ (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 31)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Vaccines Phase 4
2 Immunologic Factors Phase 4
3
Sargramostim Approved, Investigational Phase 1, Phase 2 83869-56-1, 123774-72-1
4
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
5
Testosterone Approved, Experimental, Investigational Phase 1, Phase 2 481-30-1, 58-22-0 6013 10204
6
nivolumab Approved Phase 2 946414-94-4
7
Ipilimumab Approved Phase 2 477202-00-9
8
Metformin Approved Phase 2 657-24-9 4091 14219
9 Hormone Antagonists Phase 1, Phase 2
10 Alkylating Agents Phase 1, Phase 2
11 Androgens Phase 1, Phase 2
12 Hormones Phase 1, Phase 2
13 Immunosuppressive Agents Phase 1, Phase 2
14 Antirheumatic Agents Phase 1, Phase 2
15 Antineoplastic Agents, Alkylating Phase 1, Phase 2
16 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 1, Phase 2
17 Antibodies Phase 2
18 Antineoplastic Agents, Immunological Phase 2
19 Immunoglobulins Phase 2
20 Antibodies, Monoclonal Phase 2
21 Hypoglycemic Agents Phase 2
22
acetic acid Approved 64-19-7 176
23
Proflavine Approved 92-62-6 7099
24
Fenbendazole Vet_approved 43210-67-9 3334
25 Hemostatics
26 Coagulants
27 Lugol's solution
28
Retinol acetate 127-47-9 10245972
29 Pharmaceutical Solutions
30 Anti-Infective Agents
31 Anti-Infective Agents, Local

Interventional clinical trials:

(show all 30)
# Name Status NCT ID Phase Drugs
1 A Phase IV Open-Label, Descriptive Study to Evaluate the Safety and Effectiveness on the Incidence of HPV 6, 11, 16 and 18 Related CIN 2/3 or Worse of the Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in 16- to 26-Year-Old Japanese Women Completed NCT01544478 Phase 4
2 A Scientific Evaluation of One or Two Doses of Vaccine Against Human Papillomavirus: the ESCUDDO Study Recruiting NCT03180034 Phase 4
3 A Prospective Study of Ablation of Pulmonary Focal Pure Ground Glass Opacity Unknown status NCT01429649 Phase 3
4 A Phase III Open-label Safety and Immunogenicity Study of GARDASIL™9 Administered to 9- to 26-Year-Old Females and Males in Vietnam Completed NCT03546842 Phase 3
5 A Study to Evaluate the Efficacy of Quadrivalent HPV Vaccine in Reducing the Incidence of HPV 6-, 11-, 16-, and 18-Related CIN, AIS, and Cervical Cancer, and HPV 6-, 11-, 16-, and 18-Related External Genital Warts, Vulvar Intraepithelial Neoplasia Vaginal Intraepithelial Neoplasia, Vulvar Cancer, and Vaginal Cancer in 16- to 23-Year-Old Women Completed NCT00092521 Phase 3
6 A Randomized, Placebo-Controlled, Double-Blind Study of Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine to Investigate the Safety, and Efficacy in Chinese 20 - to 45-Years-Old Women Completed NCT00834106 Phase 3
7 A Double-Blind, Controlled, Randomized, Phase III Study of the Efficacy of an HPV16/18 VLP Vaccine in the Prevention of Advanced Cervical Intraepithelial Neoplasia (CIN2, CIN3, Adenocarcinoma In Situ [AIS] and Invasive Cervical Cancer) Associated With HPV 16 or HPV 18 Cervical Infection in Healthy Young Adult Women in Costa Rica. Completed NCT00128661 Phase 3
8 A Phase 3 Randomized, Double-Blinded, Controlled With GARDASIL® Efficacy, Immunogenicity and Safety Study of V503 [a 9-Valent HPV Vaccine] in Chinese Women 20 to 45 Years of Age Recruiting NCT03998254 Phase 3 V503;Gardasil
9 A Phase 3 Open-Label Clinical Trial to Study the Immunogenicity, Safety and Tolerability of Recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine (V501) in Chinese Girls Aged 9-19 Years and Young Women Aged 20-26 Years Active, not recruiting NCT03493542 Phase 3
10 Comparison of Video-assisted Thoracoscopic Segmentectomy Versus Lobectomy for Lung Adenocarcinoma in Situ and With Microinvasion Not yet recruiting NCT02011997 Phase 3
11 A Neoadjuvant Immunologic Study of Androgen Deprivation Therapy Combined With a Granulocytemacrophage-colony Stimulating Factor F-secreting Allogeneic Prostate Cancer Vaccine and Low-dose Cyclophosphamide in Men With High-risk Localized Prostate Cancer Undergoing Radical Prostatectomy Completed NCT01696877 Phase 1, Phase 2 degarelix acetate;Cyclophosphamide;GVAX
12 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Recruiting NCT02834013 Phase 2
13 Metformin With Neoadjuvant Chemoradiation to Improve Pathologic Responses in Rectal Cancer: An Internal Pilot Study Active, not recruiting NCT03053544 Phase 2 Metformin
14 Conservative Surgery for Women With Low-risk, Early Stage Cervical Cancer Active, not recruiting NCT01048853 Phase 2
15 Morphometric Diagnosis of Atypical Glandular Lesions Using a Conventional Pap Smear From GOG-0171 Patients (Enrolled by GOG-Japan) With a Cytologic Diagnosis of Atypical Glandular Cells of Unspecified Significance (AGUS) Unknown status NCT00898144
16 Prospective Cohort Study of Telomere Biology Among Patients With Early Adenocarcinoma of the Lung Unknown status NCT02239432
17 Validation of High Resolution Microendoscope in the Screening of Cervical Cancer Precursor Lesions in Brazil (UH3 - Brazil) Unknown status NCT03195218
18 Point‐of‐Care, Real‐Time Optical Imaging to Enable Screening for Cervical Cancer and Its Precursors in Low‐Resource Settings Completed NCT02494310
19 Post Colposcopy Management of ASC-US and LSIL Pap Tests (PALS Trial): Pilot Study Completed NCT03466710
20 Comparative Analysis of CA-IX, p16, Proliferative Markers, and Human Papilloma Virus (HPV) in the Diagnosis of Significant Cervical Lesions in Patients With a Cytologic Diagnosis of Atypical Glandular Cells (AGC) Recruiting NCT00892866
21 A Prospective and Multi-center RCT Study of Lymphadenectomy Based on Intraoperative Frozen Pathology for Pulmonary Invasive Adenocarcinoma Presenting With Ground Glass Opacity Recruiting NCT03322826
22 Establishment and Evaluation for Pathological Diagnostic Criteria of Intraoperative Frozen Section of Early Stage Lung Cancer Recruiting NCT02941003
23 HSIL/ACIS/Early Cervical Cancer: What Are The Current Causative HPV Subtypes in the Era of HPV Vaccination? Recruiting NCT02937155
24 Prevalence of Anal Dysplasia and Anal Cancer in Women With Cervical, Vaginal and Vulvar Dysplasia and Cancer Recruiting NCT02140021
25 Use of High-Resolution Microendoscopy (HRME) in Patients With Adenocarcinoma In-Situ (AIS) of the Cervix Active, not recruiting NCT02206048 Proflavine
26 A Clinical Pathway for the Treatment of Multifocal Lung Adenocarcinoma Using Genome Sequencing Active, not recruiting NCT01946100
27 A Prospective, Multi-centre Post Marketing Surveillance (PMS) Cohort Study to Monitor the Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV)-16/18 L1 VLP AS04 Vaccine in Female Chinese Subjects Aged Between 9 and 45 Years, When Administered According to the Prescribing Information (PI) as Per Routine Practice. Active, not recruiting NCT03438006
28 A Clinical Test for the Treatment of Multifocal Lung Cancers Using Genome Enrolling by invitation NCT02705404
29 A Long-term Follow-up Registry-based Cohort Study of HPV Vaccine Efficacy Against Cervical Pre-cancerous Lesions and Cervical Cancers in a Cohort of Females Previously Enrolled From Finland in Study HPV-008, as Compared to a Non-intervention Population -Based Reference Cohort of Females From Finland Enrolling by invitation NCT01393470
30 Pilot Study of the Hand-held In Vivo Confocal Microscopy Probe for Detection of Cervical Intraepithelial Neoplasia Suspended NCT02574442

Search NIH Clinical Center for Adenocarcinoma in Situ

Cochrane evidence based reviews: adenocarcinoma in situ

Genetic Tests for Adenocarcinoma in Situ

Anatomical Context for Adenocarcinoma in Situ

MalaCards organs/tissues related to Adenocarcinoma in Situ:

41
Lung, Cervix, Testes, Colon, Lymph Node, Prostate, Pancreas

Publications for Adenocarcinoma in Situ

Articles related to Adenocarcinoma in Situ:

(show top 50) (show all 1226)
# Title Authors PMID Year
1
Increased HPV detection by the use of a pre-heating step on vaginal self-samples analysed by Aptima HPV assay. 38
31002831 2019
2
Endocervical adenocarcinoma in situ (AIS) with ovarian and pulmonary involvement: report of a case and review of the literature suggesting a "seed and soil hypothesis". 38
31309301 2019
3
Should pathologically non-invasive lung adenocarcinoma larger than 3 cm be classified as T1a? 38
31400323 2019
4
Can texture features improve the differentiation of infiltrative lung adenocarcinoma appearing as ground glass nodules in contrast-enhanced CT? 38
31307637 2019
5
Effectiveness on high-grade cervical abnormalities and long-term safety of the quadrivalent human papillomavirus vaccine in Japanese women. 38
30879979 2019
6
Missed Opportunities for HPV Vaccination Among Vaccine-Eligible Women with High Grade Cervical Lesions. 38
31248688 2019
7
Is one dose of human papillomavirus vaccine as effective as three?: A national cohort analysis. 38
31319173 2019
8
[Thoracoscopic Left Upper Division Segmentectomy for Multiple Ground-glass Nodules Using Preoperative Virtual-assisted Lung Mapping]. 38
31296803 2019
9
Multi-region exome sequencing reveals genomic evolution from preneoplasia to lung adenocarcinoma. 38
31278276 2019
10
Can we predict histological outcome of distinctive cohorts of patients with glandular cell abnormalities on ThinPrep Papanicolaou testing based on human papillomavirus status, age, and associated squamous abnormalities? 38
31359607 2019
11
Cytological differences between invasive and noninvasive or minimally invasive lung adenocarcinomas diagnosed in Japanese patients using needle biopsy specimens of pulmonary lesions ≤3 cm in diameter. 38
30968597 2019
12
Computer-aided diagnosis of ground-glass opacity pulmonary nodules using radiomic features analysis. 38
31167172 2019
13
Endocervical Adenocarcinoma In Situ Phenotype with Ovarian Metastasis. 38
30599504 2019
14
The new 8th TNM staging system of lung cancer and its potential imaging interpretation pitfalls and limitations with CT image demonstrations. 38
31295144 2019
15
Adenocarcinoma in situ of the uterine cervix: Clinical practice guidelines from the Italian society of colposcopy and cervical pathology (SICPCV). 38
31352128 2019
16
Detection of HPV RNA molecules in stratified mucin-producing intraepithelial lesion (SMILE) with concurrent cervical intraepithelial lesion: a case report. 38
31159808 2019
17
Efficacy of quadrivalent human papillomavirus vaccine against persistent infection and genital disease in Chinese women: A randomized, placebo-controlled trial with 78-month follow-up. 38
30122646 2019
18
Is the positive predictive value of high-grade cytology in predicting high-grade cervical disease falling due to HPV vaccination? 38
30536935 2019
19
Adenocarcinoma in situ in type I congenital pulmonary airway malformation. 38
31226882 2019
20
Value of TSCT Features for Differentiating Preinvasive and Minimally Invasive Adenocarcinoma From Invasive Adenocarcinoma Presenting as Subsolid Nodules Smaller Than 3 cm. 38
31201034 2019
21
Application of deep learning (3-dimensional convolutional neural network) for the prediction of pathological invasiveness in lung adenocarcinoma: A preliminary study. 38
31232960 2019
22
Lung Adenocarcinoma Invasiveness Risk in Pure Ground-Glass Opacity Lung Nodules Smaller than 2 cm. 38
29359309 2019
23
Role of ThinPrep liquid-based cytology in evaluation of the endocervical canal in patients with abnormal cervical screening. 38
31186178 2019
24
Problems in the reproducibility of classification of small lung adenocarcinoma: an international interobserver study. 38
31107973 2019
25
Clinicopathological Characteristics of Atypical Glandular Cells Determined by Cervical Cytology in Japan: Survey of Gynecologic Oncology Data from the Obstetrical Gynecological Society of Kinki District, Japan. 38
31048578 2019
26
Clinical analysis of percutaneous computed tomography-guided injection of cyanoacrylate for localization of 115 small pulmonary lesions in 113 asymptomatic patients. 38
30966824 2019
27
Challenges in the Pap diagnosis of endocervical adenocarcinoma in situ. 38
31097290 2019
28
The Incidence and Clinical Significance of Atypical Glandular Cells of Undetermined Significance on Cervical Pap Smears. 38
31242982 2019
29
Expression of Markers of Müllerian Clear Cell Carcinoma in Primary Cervical and Vaginal Gastric-type Adenocarcinomas. 38
29901522 2019
30
CT-guided Microcoil Pulmonary Nodule Localization prior to Video-assisted Thoracoscopic Surgery: Diagnostic Utility and Recurrence-Free Survival. 38
30720402 2019
31
Evaluation of Folate Receptor-Mediated Cervical Dyeing as a Method for Detection of Cervical Lesions. 38
30817686 2019
32
Estimated Number of Cases of High-Grade Cervical Lesions Diagnosed Among Women - United States, 2008 and 2016. 38
30998672 2019
33
Cervical adenocarcinoma in situ: Human papillomavirus types and incidence trends in five states, 2008-2015. 38
30980692 2019
34
Histogram analysis combined with morphological characteristics to discriminate adenocarcinoma in situ or minimally invasive adenocarcinoma from invasive adenocarcinoma appearing as pure ground-glass nodule. 38
30927953 2019
35
A comparison between 2- and 3-dimensional approaches to solid component measurement as radiological criteria for sublobar resection in lung adenocarcinoma ≤ 2 cm in size. 38
30968225 2019
36
RANZCOG Fellows' adherence to guidelines following cytological prediction of cervical adenocarcinoma-in-situ: Cause for concern? 38
30284744 2019
37
Histogram-based models on non-thin section chest CT predict invasiveness of primary lung adenocarcinoma subsolid nodules. 38
30979926 2019
38
Trends in High-grade Cervical Lesions and Cervical Cancer Screening in 5 States, 2008-2015. 38
30137283 2019
39
Absolute risks of cervical precancer among women who fulfill exiting guidelines based on HPV and cytology cotesting. 38
30861114 2019
40
Distinctive clinicopathological features of adenocarcinoma in situ and minimally invasive adenocarcinoma of the lung: A retrospective study. 38
30797486 2019
41
Histopathology of Women with “Atypical Squamous Cells Cannot Exclude High-Grade Squamous Intraepithelial Lesion” (ASC-H) Smears 38
30909664 2019
42
A case study of gastric-type adenocarcinoma in situ of the uterine cervix. 38
30417947 2019
43
Cervical Screening Results Leading to Detection of Adenocarcinoma in Situ of the Uterine Cervix 38
30803195 2019
44
Smear cytological features of large cell neuroendocrine carcinoma of the uterine cervix in pregnancy: A case report and review of the literature. 38
30461217 2019
45
PD-L1 Expression in Non-Small-Cell Lung Cancer Including Various Adenocarcinoma Subtypes. 38
30282880 2019
46
Recent increase in incidence of cervical precancerous lesions in Norway: Nationwide study from 1992 to 2016. 38
30734284 2019
47
An Observational Study of Deep Learning and Automated Evaluation of Cervical Images for Cancer Screening. 38
30629194 2019
48
Expressions of ATF6, XBP1, and GRP78 in normal tissue, atypical adenomatous hyperplasia, and adenocarcinoma of the lung. 38
30121368 2019
49
Utility of imaging modalities for predicting carcinogenesis in lobular endocervical glandular hyperplasia. 38
31415639 2019
50
Three-dimensional navigation-guided thoracoscopic combined subsegmentectomy for intersegmental pulmonary nodules. 38
30390378 2019

Variations for Adenocarcinoma in Situ

Expression for Adenocarcinoma in Situ

Search GEO for disease gene expression data for Adenocarcinoma in Situ.

Pathways for Adenocarcinoma in Situ

GO Terms for Adenocarcinoma in Situ

Biological processes related to Adenocarcinoma in Situ according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 G1/S transition of mitotic cell cycle GO:0000082 9.72 MCM2 CDKN2A CDKN1A
2 Ras protein signal transduction GO:0007265 9.7 KRAS CDKN2A CDKN1A
3 cochlea development GO:0090102 9.62 PAX2 MCM2
4 negative regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045736 9.62 CDKN2A CDKN1A
5 cellular senescence GO:0090398 9.61 CDKN2A CDKN1A
6 calcium-independent cell-cell adhesion via plasma membrane cell-adhesion molecules GO:0016338 9.61 CLDN10 CLDN1
7 positive regulation of branching involved in ureteric bud morphogenesis GO:0090190 9.6 PAX8 PAX2
8 positive regulation of cellular senescence GO:2000774 9.59 KRAS CDKN2A
9 negative regulation of phosphorylation GO:0042326 9.58 CDKN2A CDKN1A
10 urogenital system development GO:0001655 9.58 PAX8 PAX2
11 replicative senescence GO:0090399 9.57 CDKN2A CDKN1A
12 mesonephros development GO:0001823 9.56 PAX8 PAX2
13 mesenchymal to epithelial transition involved in metanephros morphogenesis GO:0003337 9.54 PAX8 PAX2
14 regulation of metanephric nephron tubule epithelial cell differentiation GO:0072307 9.51 PAX8 PAX2
15 pronephros development GO:0048793 9.49 PAX8 PAX2
16 metanephric epithelium development GO:0072207 9.48 PAX8 PAX2
17 positive regulation of mesenchymal to epithelial transition involved in metanephros morphogenesis GO:0072108 9.46 PAX8 PAX2
18 metanephric nephron tubule formation GO:0072289 9.43 PAX8 PAX2
19 metanephric distal convoluted tubule development GO:0072221 9.4 PAX8 PAX2
20 negative regulation of mesenchymal cell apoptotic process involved in metanephros development GO:1900212 9.37 PAX8 PAX2
21 pronephric field specification GO:0039003 9.32 PAX8 PAX2
22 positive regulation of metanephric DCT cell differentiation GO:2000594 9.26 PAX8 PAX2
23 negative regulation of mesenchymal cell apoptotic process involved in metanephric nephron morphogenesis GO:0072305 9.16 PAX8 PAX2
24 negative regulation of apoptotic process involved in metanephric nephron tubule development GO:1900218 8.96 PAX8 PAX2
25 negative regulation of apoptotic process involved in metanephric collecting duct development GO:1900215 8.62 PAX8 PAX2

Molecular functions related to Adenocarcinoma in Situ according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 8.62 CDKN2A CDKN1A

Sources for Adenocarcinoma in Situ

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....